News Conference News ESC Heart Failure 2025 HELIOS-B: Additional Data Affirm Benefits of Vutrisiran for ATTR-CM Todd Neale May 19, 2025
News Daily News FDA Approves First ‘Near-Complete’ Stabilizer to Treat ATTR Cardiomyopathy L.A. McKeown November 25, 2024
News Conference News ESC 2023 STEP-HFpEF: Semaglutide Cuts Weight and Symptoms, Boosts Function Shelley Wood August 25, 2023
News Conference News ESC Heart Failure 2022 Patch-Pump Delivery of Subcutaneous Furosemide Opens Options in HF Shelley Wood May 26, 2022
News Conference News ACC 2022 New HF Guidelines Stress Four-Drug Approach, ‘HFmrEF,’ Amyloidosis Options, and More Shelley Wood April 01, 2022
News Daily News In the US, HF Prevalence—and Costs—Rising Steeply: HFSA Report Michael O'Riordan January 27, 2022
News Daily News Meta-analysis of Pivotal SGLT2 Inhibitor Trials Boosts Hopes in HFpEF L.A. McKeown December 07, 2021
News Daily News Dapagliflozin US Cost-effectiveness Data Expose Barriers to HF Care Shelley Wood May 27, 2021
News Features Year in Review: SGLT2 Inhibition, Lipid-Lowering Make Waves in Clinical Cardiology in 2019 Todd Neale December 10, 2019
News Daily News Heart Failure Risk Following 'Silent' MI Warrants Scrutiny: ARIC Analysis Caitlin E. Cox January 08, 2018